Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.

Dubois Cauwelaert N, Desbien AL, Hudson TE, Pine SO, Reed SG, Coler RN, Orr MT.

PLoS One. 2016 Jan 5;11(1):e0146372. doi: 10.1371/journal.pone.0146372. eCollection 2016.

2.

Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cells.

Baldwin SL, Ching LK, Pine SO, Moutaftsi M, Lucas E, Vallur A, Orr MT, Bertholet S, Reed SG, Coler RN.

J Immunol. 2013 Sep 1;191(5):2514-2525. doi: 10.4049/jimmunol.1301161. Epub 2013 Jul 31.

3.

Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment.

Coler RN, Bertholet S, Pine SO, Orr MT, Reese V, Windish HP, Davis C, Kahn M, Baldwin SL, Reed SG.

J Infect Dis. 2013 Apr 15;207(8):1242-52. doi: 10.1093/infdis/jis425. Epub 2012 Aug 13.

4.

Pre-existing adenovirus immunity modifies a complex mixed Th1 and Th2 cytokine response to an Ad5/HIV-1 vaccine candidate in humans.

Pine SO, Kublin JG, Hammer SM, Borgerding J, Huang Y, Casimiro DR, McElrath MJ.

PLoS One. 2011 Apr 13;6(4):e18526. doi: 10.1371/journal.pone.0018526.

5.

A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis.

Bertholet S, Ireton GC, Ordway DJ, Windish HP, Pine SO, Kahn M, Phan T, Orme IM, Vedvick TS, Baldwin SL, Coler RN, Reed SG.

Sci Transl Med. 2010 Oct 13;2(53):53ra74. doi: 10.1126/scitranslmed.3001094.

6.

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis.

Nascimento E, Fernandes DF, Vieira EP, Campos-Neto A, Ashman JA, Alves FP, Coler RN, Bogatzki LY, Kahn SJ, Beckmann AM, Pine SO, Cowgill KD, Reed SG, Piazza FM.

Vaccine. 2010 Sep 14;28(40):6581-7. doi: 10.1016/j.vaccine.2010.07.063. Epub 2010 Aug 3.

PMID:
20688040
7.

Polymorphisms in toll-like receptor 4 and toll-like receptor 9 influence viral load in a seroincident cohort of HIV-1-infected individuals.

Pine SO, McElrath MJ, Bochud PY.

AIDS. 2009 Nov 27;23(18):2387-95. doi: 10.1097/QAD.0b013e328330b489.

Supplemental Content

Support Center